Betty C. Pang

Counsel
San Francisco
  • 505 Montgomery Street
  • Suite 2000
  • San Francisco, CA 94111-6538
  • USA
Profile Experience

Dr. Pang represents private equity firms and investment banks, healthcare providers and health systems, and life science companies, including pharmaceutical, medical device and biotechnology companies, and medical suppliers on regulatory issues pertaining to fraud and abuse, self-referral and government program reimbursement compliance, and facility and provider licensing issues, including:

  • Mergers and acquisitions
  • Initial public offerings
  • Financings
  • Joint ventures
  • Government investigations
  • Day-to-day regulatory counseling

Dr. Pang is a member of the American Health Lawyers Association, the California Society for Healthcare Attorneys, and the American Bar Association Health Law Section.

In connection with her transactional practice and general representation of healthcare industry clients, Dr. Pang also represents commercial lenders, private equity firms, and investment banks in healthcare transactions.

Over the last several years, Dr. Pang has advised on the following matters:

Mergers and Acquisitions
  • US$275 million sale of Pionyr Immunotherapeutics to Gilead Sciences
  • US$1.4 billion acquisition by KKR of PharMerica
  • US$354 million acquisition by KKR of Covenant Surgical Partners
  • Acquisition of a majority interest by ABRY Partners in Oliver Street Dermatology Associate Holdings LLC d/b/a Dermatology Associates
  • US$84 million acquisition by General Electric Capital and MSN Acquisition of Medical Staffing Network Holdings via a Section 363 bankruptcy auction
  • US$3.2 billion acquisition by Clayton, Dubilier & Rice, of Emergency Medical Services
  • US$363 million acquisition by Leonard Green & Partners L.P. of Prospect Medical Holdings
  • US$195 million sale of Bonti to Allergan
  • US$81 million acquisition by Entellus Medical of Spirox
  • Acquisition by Walgreen Co. of Crescent Healthcare 
Capital Markets
  • Aimmune Therapeutics in its US$160 million IPO
  • Ascendis Pharma in its US$500 million IPO
  • Corvus Pharmaceuticals in its US$60 million follow-on offering
  • CytomX Therapeutics in its US$116.9 million IPO
  • Gritstone Oncology in its US$74.8 million offering
  • Teladoc in its US$180 million IPO
  • Underwriters in SmileDirectClub’s US$1.35 billion IPO
  • Underwriters in National Vision Holdings’ US$400 million IPO
  • Underwriters in Menlo Therapeutics’ US$136.85 million follow-on offering
  • Underwriters in Mirium Pharmaceuticals’ US$75 million IPO
  • Underwriters in BridgeBio Pharma’s US$348.5 million IPO
  • Underwriters in Athenex’s US$65 million IPO
  • Underwriters in Ultragenyx Pharmaceutical’s US$304 million IPO and US$250 million stock offering
  • Underwriters in Veracyte’s US$147 million IPO
  • Underwriters in Eiger BioPharmaceuticals’s US$49.5 million IPO
  • Underwriters in Harpoon Therapeutics’s US$75.6 million IPO
  • Underwriters in BioMarin Pharmaceutical’s US$450 million debt offering
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.